31 results about "Urothelium" patented technology

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres tothe urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

The invention discloses a traditional Chinese medicinal flushing liquid for a urinary system. The flushing liquid consists of the cooking extracts of coptis chinensis and scutellaria baicalensis, wherein the mass ratio of the coptis chinensis to the scutellaria baicalensis is 1 to 1; the cooking extracts of the coptis chinensis and the scutellaria baicalensis are extracted by the following processes: grinding the coptis chinensis and the scutellaria baicalensis into fine powder, respectively soaking the coptis chinensis and the scutellaria baicalensis fine powder in distilled water for 0.8-2hr, and boiling twice with slow fire, wherein each time lasts for 20-40min; decompressing and filtering, combining filtrates of two times, decompressing, concentrating and recovering a solvent, wherein medicinal liquid concentration is 1g of crude drugs in per milliliter; and regulating pH value to 6-7 and regulating osmotic pressure by virtue of sodium chloride and sodium hydrogen carbonate. The traditional Chinese medicinal flushing liquid can be used for inhibiting the growth of bacteria, relieving irritative symptoms, promoting mucosa repair and improving local immune state; by regulating the pH value and the osmotic pressure by virtue of the sodium chloride and the sodium hydrogen carbonate, the traditional Chinese medicinal flushing liquid is more adaptive to the physiological characteristics of urothelium regional anatomy; the flushing liquid is suitable for various patients of indwelling catheter and has a significant treating effect on related infections of catheter. The flushing liquid disclosed by the invention is low in production cost and capable of remarkably reducing the flushing cost in urinary operations.

The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and / or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.

A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and / or inhibiting its binding to its ETA and / or ETB receptors are also provided.

The invention discloses a urine detection kit for diagnosing urothelium carcinoma. The urine detection kit comprises capture reagent, detection reagent, coating buffer solution, scrubbing solution, color-producing reagent and termination reagent. The capture reagent is anti-Neu5Gc primary antibody, and the detection agent is anti-Neu5Gc second antibody. The kit disclosed by the invention is high in sensitivity and has the advantage of the urine exfoliocytology, the problem that the urine exfoliocytology is low in sensitivity is overcome, and the kit can be used for the early screening of the urothelium carcinoma.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and / or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.

The invention provides a new human urothelial carcinoma tumor marker-human tumor necrosis factor receptor superfamily TNFRSF25 and a hybridoma cell generating a monoclonal antibody resisting the tumor marker and a monoclonal antibody DTUC1 secreted thereby, wherein the monoclonal antibody DTUC1 is secreted by the hybridoma with collection number CGMCC No.8118. The monoclonal antibody DTUC1 is in positive reaction with the human urothelial carcinoma tissue and urothelial carcinoma cell lines such as 5637, UMUC3, SW780, J82, T24 and RT4, and is not in cross reaction with the human normal urothelium tissue and other non-urothelial carcinoma cells; according to mass spectrometric detection, the identified antigen is TNFRSF25. The invention also provides an in-vitro diagnosis kit comprising the monoclonal antibody DTUC1 and a method for detecting the content of tumor markers in urine by use of the monoclonal antibody DTUC1.

The invention discloses a porous bladder acellular matrix retaining bioactive factors and a preparation method thereof. A bladder of a pig, a rabbit, a dog or cattle is handled by digestive juice, hypotonic buffer solution, hypertonic buffer solution with surfactants, buffer solution with nuclease, and deionized water. An abacterial bladder acellular matrix is obtained by cooling, freezing out and sterilizing. The bladder acellular matrix is not provided with cells, an urinary tract epithelial layer, a submucous layer or a blood circulatory system, thus having good biocompatibility and appropriate ultrastructural structure. Bioactive factors are retained, including cell adhesive factors, growth factors and chemokines. Therefore, the bladder acellular matrix is an ideal scaffold material for a bladder in tissue engineering.

The invention discloses urothelium carcinoma surgical equipment which comprises a handheld pipe for being extended into a ureter, a clamping connection head arranged at one end of the handheld pipe and used for clamping the inner wall of the ureter and perfusion design convenient for chemotherapeutics, the clamping connection head comprises a connection seat and an airbag sleeving the connection seat, the connections seat is fixedly connected with the end of the handheld pipe, the airbag is communicated with the inside of the handheld pipe, and a plurality of overhead hooks are distributed onthe outer side face of the airbag. When the handheld pipe is extended into the ureter, the airbag is inflated to expand, and the overhead hooks hook the inner wall of the ureter.